MannKind (NASDAQ:MNKD – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Risk & Volatility
MannKind has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Institutional and Insider Ownership
49.5% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares MannKind and Stoke Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MannKind | $348.97 million | 3.66 | $5.86 million | ($0.23) | -17.24 |
| Stoke Therapeutics | $184.42 million | 9.42 | -$6.89 million | ($3.77) | -7.04 |
MannKind has higher revenue and earnings than Stoke Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares MannKind and Stoke Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MannKind | -18.10% | N/A | -10.01% |
| Stoke Therapeutics | -862.07% | -67.30% | -58.52% |
Analyst Recommendations
This is a summary of recent ratings and target prices for MannKind and Stoke Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MannKind | 1 | 2 | 7 | 0 | 2.60 |
| Stoke Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
MannKind currently has a consensus target price of $8.50, suggesting a potential upside of 114.32%. Stoke Therapeutics has a consensus target price of $44.17, suggesting a potential upside of 66.32%. Given MannKind’s higher possible upside, analysts clearly believe MannKind is more favorable than Stoke Therapeutics.
Summary
MannKind beats Stoke Therapeutics on 8 of the 14 factors compared between the two stocks.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
About Stoke Therapeutics
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
